Entera Bio Ltd. EBIT

EBIT of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.


Highlights and Quick Summary

  • EBIT for the quarter ending June 29, 2020 was $-3.53 Million (a 21.83% increase compared to previous quarter)
  • Year-over-year quarterly EBIT increased by 24.23%
  • Annual EBIT for 2019 was $-11.5 Million (a 5.46% increase from previous year)
  • Annual EBIT for 2018 was $-10.9 Million (a -4.25% decrease from previous year)
  • Twelve month EBIT ending June 29, 2020 was $-12.8 Million (a 13.31% increase compared to previous quarter)
  • Twelve month trailing EBIT increased by 22.16% year-over-year
Trailing EBIT for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-12.8 Million $-11.3 Million $-11.5 Million $-10.4 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of Entera Bio Ltd.

Most recent EBITof ENTX including historical data for past 10 years.

Interactive Chart of EBIT of Entera Bio Ltd.

Entera Bio Ltd. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.53 $-2.9
2019 $-3.5 $-2.84 $-2.03 $-3.09 $-11.45
2018 $-2.48 $-2.87 $-1.36 $-4.16 $-10.86
2017 $-11.34

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.